Cargando…

Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged “no-problems”

PURPOSE: The goal of the present study was to determine factors related to a ceiling effect (CE) on the EQ-5D-5L among Japanese patients with prostate cancer (PC). METHODS: An existent cross-sectional observational study dataset was used. Patients were ≥ 20 years of age and diagnosed with PC. For CE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murasawa, Hideki, Sugiyama, Takayuki, Matsuoka, Yuki, Okabe, Takashi, Wakumoto, Yoshiaki, Tanaka, Nobumichi, Sugimoto, Mikio, Oyama, Masafumi, Fujimoto, Kiyohide, Horie, Shigeo, Funagoshi, Masaru, Arakawa, Ichiro, Noto, Shinichi, Shimozuma, Kojiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028791/ https://www.ncbi.nlm.nih.gov/pubmed/31583618 http://dx.doi.org/10.1007/s11136-019-02316-4

Ejemplares similares

Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D
por: Shiroiwa, Takeru, et al.
Publicado: (2015)

Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
por: Hagiwara, Yasuhiro, et al.
Publicado: (2020)

Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L
por: Izumi, Shoki, et al.
Publicado: (2023)

Psychometric properties of the Japanese version of the EQ-5D-Y by self-report and proxy-report: reliability and construct validity
por: Shiroiwa, T., et al.
Publicado: (2019)

Scale agreement, ceiling and floor effects, construct validity, and relative efficiency of the PROPr and EQ-5D-3L in low back pain patients
por: Klapproth, Christoph Paul, et al.
Publicado: (2023)

Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients
por: Golicki, Dominik, et al.
Publicado: (2014)

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial
por: Oyama, Masafumi, et al.
Publicado: (2017)

Population norms for the EQ-5D-3L and EQ-5D-5L in Romania
por: Olariu, Elena, et al.
Publicado: (2023)

Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments
por: Wolfs, Claire AG, et al.
Publicado: (2007)

Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
por: Wille, Nora, et al.
Publicado: (2010)

Whitewash for Ceilings
Publicado: (1890)

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
por: Herdman, M., et al.
Publicado: (2011)

Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults
por: Ferreira, Lara N., et al.
Publicado: (2016)

Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
por: Mulhern, Brendan, et al.
Publicado: (2018)

Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values
por: Selivanova, Anna, et al.
Publicado: (2018)

Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population
por: You, Ruxu, et al.
Publicado: (2020)

Validity of EQ-5D-5L in stroke
por: Golicki, Dominik, et al.
Publicado: (2014)

Valuation of the EQ-5D-5L in Taiwan
por: Lin, Hsiang-Wen, et al.
Publicado: (2018)

Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients
por: Pattanaphesaj, Juntana, et al.
Publicado: (2015)

Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
por: Mulhern, Brendan, et al.
Publicado: (2018)

EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories
por: Kreimeier, Simone, et al.
Publicado: (2019)

The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa
por: Bató, Alex, et al.
Publicado: (2021)

Psychometric properties of the EQ-5D-5L compared with EQ-5D-3L in cancer patients in Iran
por: Moradi, Nasrin, et al.
Publicado: (2022)

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
por: Kunogi, Hiroaki, et al.
Publicado: (2016)

Breaking the Crystal Ceiling
por: Gebel Berg, Erika
Publicado: (2015)

Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients
por: Fitriana, Titi Sahidah, et al.
Publicado: (2021)

Comparison of the EQ-5D-Y-5L, EQ-5D-Y-3L and PedsQL in children and adolescents
por: Verstraete, Janine, et al.
Publicado: (2022)

Impact of nausea/vomiting on EQ-5D-5L utility scores in patients taking iron preparations for heavy menstrual bleeding or anemia
por: Ito, Kyoko, et al.
Publicado: (2023)

Correspondence between EQ-5D health state classifications and EQ VAS scores
por: Whynes, David K
Publicado: (2008)

EQ-5D-5L Polish population norms
por: Golicki, Dominik, et al.
Publicado: (2015)

German Value Set for the EQ-5D-5L
por: Ludwig, Kristina, et al.
Publicado: (2018)

The Indonesian EQ-5D-5L Value Set
por: Purba, Fredrick Dermawan, et al.
Publicado: (2017)

EQ-5D-5L Slovenian population norms
por: Prevolnik Rupel, Valentina, et al.
Publicado: (2020)

An EQ-5D-5L Value Set for Vietnam
por: Mai, Vu Quynh, et al.
Publicado: (2020)

The EQ-5D-5L Valuation Study in Egypt
por: Al Shabasy, Sahar, et al.
Publicado: (2021)

An EQ-5D-5L Value Set for Belgium
por: Bouckaert, Nicolas, et al.
Publicado: (2022)

EQ-5D-5L Population Norms for Italy
por: Meregaglia, Michela, et al.
Publicado: (2022)

EQ-5D-5L Portuguese population norms
por: Ferreira, Pedro L., et al.
Publicado: (2023)

EQ-5D-5L Value Set for Slovenia
por: Prevolnik Rupel, Valentina, et al.
Publicado: (2023)

Cross-cultural measurement equivalence of the 5-level EQ-5D (EQ-5D-5L) in patients with type 2 diabetes mellitus in Singapore
por: Wang, Ye, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aqikcv2hrqv6e7csgg2pkgru6d